What are first-line options for treatment of stage IV non–small cell lung cancer (NSCLC) in patients with a sensitizing endothelial growth factor receptor (EGFR) mutation?

Updated: Jul 15, 2021
  • Author: Winston W Tan, MD, FACP; Chief Editor: Nagla Abdel Karim, MD, PhD  more...
  • Print

First-line therapy:

  • In patients with T790M, L858R, or exon 19 deletion mutations, osimertinib should be offered.If osimertinib is not available, gefitinib with chemotherapy or dacomitinib may be offered.
  • Other options that may be offered include afatinib, erlotinib/bevacizumab, erlotinib/ramucirumab, gefitinib, erlotinib, or icotinib
  • In patients with a PS of 3, an EGFR tyrosine kinase inhibitor (TKI) may be offered.
  • In patients with  EGFR mutations other than exon 20 insertion mutations, T790M, L858R, or exon 19 deletion alterations, afatinib may be offered.
  • In patients with EGFR exon 20 insertion mutation causing resistance to first- and second-generation EGFR TKIs, doublet chemotherapy with or without bevacizumab or standard treatment for stage IV NSCLC without driver mutations may be offered.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!